Back to results
US 2022/0064280 A1Published application
Methods of treating psoriasis
AssigneeEli Lilly and Company
InventorsSTUART WILLIAM FRIEDRICH, Paul Alan Klekotka, Jay Lawrence Tuttle
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to the treatment of psoriasis with an antibody that binds to the p19 subunit of human IL-23, in particular dosage regimens for the treatment of the disease.
Claims3
1-27. (canceled)
A method of treating psoriasis comprising administering mirikizumab to a patient, said method comprising:
- a) administering four induction doses of mirikizumab to the patient by subcutaneous injection at 4 week intervals, wherein each induction dose comprises 250 mg of mirikizumab;
- and
- b) administering maintenance doses of mirikizumab to the patient by subcutaneous injection at 8 week intervals, wherein the first maintenance dose is administered 4 weeks after the last induction dose is administered and wherein each maintenance dose comprises 125 mg or 250 mg of mirikizumab,
- wherein the psoriasis is moderate to severe plaque psoriasis.
1 more element
29-71. (canceled)
Dependencies are inferred from the claim text.